Enzymatic pathways involved in the generation of endothelin-1(1-31) from exogenous big endothelin-1 in the rabbit aorta

Br J Pharmacol. 2006 Jun;148(4):527-35. doi: 10.1038/sj.bjp.0706735. Epub 2006 Apr 24.

Abstract

We investigated whether blood vessels contribute to the production of ET-1(1-31) from exogenous big endothelin-1 (BigET-1) in the rabbit and assessed which enzymes are involved in this process. Vascular reactivity experiments, using standard muscle bath procedures, showed that BigET-1 induces contraction in endothelium-intact rabbit aortic rings. Preincubation of the rings with phosphoramidon, CGS35066 or thiorphan reduced BigET-1-induced contraction. Conversely, chymostatin did not affect BigET-1-induced contraction. Thiorphan and phosphoramidon, but not CGS35066 or chymostatin, reduced ET-1(1-31)-induced contraction. None of the enzymatic inhibitors affected the contraction afforded by ET-1.BQ123-, but not BQ788-, selective antagonists for ET(A) and ET(B) receptors, respectively, produced concentration-dependent rightward displacements of the ET-1(1-31) and ET-1 concentration-response curves. By the use of enzymatic assays, we found that the aorta, as well as the heart, lung, kidney and liver, possess a chymase-like activity. Enzyme immunoassays detected significant levels of Ir-ET-1(1-31) in bathing medium of aortas after the addition of BigET-1 (30 nM). Neither thiorphan nor chymostatin altered the levels of Ir-ET-1(1-31). Conversely, the levels of Ir-ET-1(1-31) were increased in the presence of phosphoramidon. This marked increase of the 31-amino-acid peptide was abolished when phosphoramidon and chymostatin were added simultaneously. The major new finding of the present work is that the rabbit aorta generates ET-1(1-31) from exogenously administered BigET-1. Additionally, by measuring the production of ET-1(1-31), we showed that a chymase-like enzyme is involved in this process when ECE and NEP are inhibited by phosphoramidon. Our results also suggest that ET-1(1-31) is an alternate intermediate in the production of ET-1 following BigET-1 administration. Finally, we showed that NEP is the predominant enzymatic pathway involved in the cleavage of ET-1(1-31) to a bioactive metabolite that will act on ET(A) receptors to induce contraction in the rabbit aorta.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Aorta / drug effects
  • Aorta / metabolism*
  • Aspartic Acid Endopeptidases / physiology
  • Chymases
  • Dose-Response Relationship, Drug
  • Endothelin-1 / analogs & derivatives*
  • Endothelin-1 / biosynthesis
  • Endothelin-1 / metabolism*
  • Endothelin-1 / pharmacology
  • Endothelin-Converting Enzymes
  • Female
  • Male
  • Metalloendopeptidases / physiology
  • Neprilysin / physiology
  • Oligopeptides / pharmacology
  • Peptide Fragments / biosynthesis*
  • Peptide Fragments / pharmacology
  • Peptides, Cyclic / pharmacology
  • Piperidines / pharmacology
  • Rabbits
  • Serine Endopeptidases / physiology
  • Vasoconstriction / drug effects

Substances

  • Endothelin-1
  • Oligopeptides
  • Peptide Fragments
  • Peptides, Cyclic
  • Piperidines
  • endothelin-1 (1-31)
  • BQ 788
  • Serine Endopeptidases
  • Chymases
  • Aspartic Acid Endopeptidases
  • Metalloendopeptidases
  • Neprilysin
  • Endothelin-Converting Enzymes
  • cyclo(Trp-Asp-Pro-Val-Leu)